Human papillomavirus-related head and neck tumors: clinical and research implication

Purpose of review High-risk human papillomaviruses (HPVs) are implicated in the development of a subset of head and neck squamous cell cancers (HNSCCs), especially those arising from the lingual or palatine tonsils. HPV-associated HNSCCs represent a different disease entity from those associated with the traditional risk factors of tobacco and alcohol use. The demonstration that HPV is causally associated with a subset of HNSCC has tremendous clinical and research implications. Recent findings In recent years, there has been an increase in the annual incidence of HPV-related HNSCC in the United States and Europe. It has now become clear that a subset of HNSCC is a sexually transmitted disease with distinct pathogenesis and clinical/pathological features. HPV-associated HNSCCs have a better prognosis compared with stage-matched non-HPV-related HNSCC in the majority of studies. Research efforts are now focusing on deintensification of treatment to reduce treatment-associated morbidity. HPV-targeted therapies are under investigation. Summary The increasing incidence of HPV-related HNSCC has led to the development of novel research strategies in HNSCC. This review summarizes the epidemiology, clinical presentation, molecular pathogenesis, diagnosis, and therapy of HPV-associated HNSCC; it also summarizes how a better understanding of the molecular pathogenesis of HPV-associated HNSCC is expected to change treatment.

[1]  A. Psyrri,et al.  E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. , 2009, Journal of the National Cancer Institute.

[2]  F. Berrino,et al.  Human papillomavirus in HNSCC: a European epidemiologic perspective. , 2008, Hematology/oncology clinics of North America.

[3]  A. Cmelak,et al.  Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. , 2008, Journal of the National Cancer Institute.

[4]  C. R. Leemans,et al.  A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen , 2007, International journal of cancer.

[5]  Carole Fakhry,et al.  Case-control study of human papillomavirus and oropharyngeal cancer. , 2007, The New England journal of medicine.

[6]  L. Mariani,et al.  High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D. Rimm,et al.  Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Y. Sugita,et al.  DNA Vaccine against Hamster Oral Papillomavirus-associated Oral Cancer , 2005, The Journal of international medical research.

[9]  Cosette M Wheeler,et al.  Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. , 2005, The Lancet. Oncology.

[10]  B. Schmidt,et al.  Tongue and tonsil carcinoma , 2005, Cancer.

[11]  C. Wheeler,et al.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomized, controlled trial , 2005 .

[12]  S. Syrjänen Human papillomavirus (HPV) in head and neck cancer. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[13]  B. Hansson,et al.  Strong association between infection with human papillomavirus and oral and oropharyngeal squamous cell carcinoma: A population-based case-control study in southern Sweden , 2005, Acta oto-laryngologica.

[14]  Daron G Ferris,et al.  Efficacy of a bivalent L 1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women : a randomised controlled trial , 2005 .

[15]  Daron G Ferris,et al.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial , 2004, The Lancet.

[16]  M. Grace,et al.  Mechanisms of Human Papillomavirus-Induced Oncogenesis , 2004, Journal of Virology.

[17]  Shwu‐Yuan Wu,et al.  Human papillomavirus (HPV) origin-binding protein associates with mitotic spindles to enable viral DNA partitioning , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[18]  R. Biggar,et al.  Changing patterns of tonsillar squamous cell carcinoma in the United States , 2000, Cancer Causes & Control.

[19]  K. Shah,et al.  Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  B. Rose,et al.  Human papillomavirus positivity predicts favourable outcome for squamous carcinoma of the tonsil , 2003, International journal of cancer.

[21]  N. Kiviat,et al.  p16INK4a Expression Correlates with Degree of Cervical Neoplasia: A Comparison with Ki-67 Expression and Detection of High-Risk HPV Types , 2003, Modern Pathology.

[22]  L. Turek,et al.  Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx , 2003, International journal of cancer.

[23]  J. Lindholm,et al.  Human papillomavirus type 16 is episomal and a high viral load may be correlated to better prognosis in tonsillar cancer , 2002, International journal of cancer.

[24]  S. Devesa,et al.  Oral cavity and pharynx cancer incidence rates in the United States, 1975-1998. , 2002, Oral oncology.

[25]  J. Laissue,et al.  Human papillomavirus positive squamous cell carcinoma of the oropharynx , 2001, Cancer.

[26]  P. Fuchs,et al.  Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. , 2001, The New England journal of medicine.

[27]  S. Schwartz,et al.  Human Papillomavirus Infection and Survival in Oral Squamous Cell Cancer: A Population-Based Study , 2001, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[28]  M. Lehtinen,et al.  Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. , 2001, The New England journal of medicine.

[29]  T. Wu,et al.  Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen , 2001, Gene Therapy.

[30]  D. DiMaio,et al.  Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[31]  K. Hemminki,et al.  Second primary cancer after in situ and invasive cervical cancer. , 2000, Epidemiology.

[32]  D. Sidransky,et al.  Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. , 2000, Journal of the National Cancer Institute.

[33]  R. Biggar,et al.  Aetiological parallel between tonsillar and anogenital squamous-cell carcinomas , 1999, The Lancet.

[34]  H. Tideman An association of HPV 16 with squamous cell carcinoma of Waldeyer's tonsillar ring , 1999 .

[35]  G. Mcquillan,et al.  Herpes simplex virus type 2 in the United States, 1976 to 1994. , 1998, The New England journal of medicine.

[36]  T. Tan,et al.  In vitro and in vivo inhibition of human papillomavirus type 16 E6 and E7 genes. , 1995, Cancer research.

[37]  J. Shay,et al.  Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. , 1994, Cancer research.

[38]  M. Skolnick,et al.  A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.

[39]  R. Hruban,et al.  Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. , 1994, Cancer research.

[40]  A. Swoboda,et al.  Tonsillar carcinoma in a renal graft recipient treated with cyclosporine A. , 1993, Clinical nephrology.

[41]  E. de Villiers,et al.  Papillomavirus DNA in human tongue carcinomas , 1985, International journal of cancer.

[42]  R. Ting,et al.  In Vitro and in Vivo Inhibition of Human Papillomavirus Type 16 E 6 and E 7 Genes , 2022 .